NCT05773326View on ClinicalTrials.gov

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
High Grade GliomaGliomaGlioma, MalignantGlioblastoma
Interventions
DRUG

Temsirolimus

TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.

Trial Locations (1)

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

All Listed Sponsors
collaborator

Barrow Neurological Institute

OTHER

collaborator

Ivy Brain Tumor Center

OTHER

lead

Nader Sanai

OTHER